Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate

The biological performance of Oryzalin was improved by incorporation in liposomes with reduction of toxicity and haemolytic activity and increment of accumulation in the target organs of the disease (leishmaniasis). Oryzalin (ORZ) is a dinitroaniline that has attracted increasing interest for the tr...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2012-10, Vol.82 (2), p.281-290
Main Authors: Lopes, Rui M., Corvo, M. Luísa, Eleutério, Carla V., Carvalheiro, Manuela C., Scoulica, Effie, Cruz, M. Eugénia M.
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Cell Line
Chemistry, Pharmaceutical
Dinitroanilines
Dinitrobenzenes - administration & dosage
Dinitrobenzenes - chemistry
Drug Carriers - chemistry
Drug Stability
General pharmacology
Humans
Leishmaniasis
Leishmaniasis - drug therapy
Liposomes
Liposomes - administration & dosage
Liposomes - chemistry
Male
Medical sciences
Mice
Monocytes - drug effects
Nanomedicines
Oryzalin
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solubility
Sulfanilamides - administration & dosage
Sulfanilamides - chemistry
Suspensions - administration & dosage
Suspensions - chemistry
Water - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The biological performance of Oryzalin was improved by incorporation in liposomes with reduction of toxicity and haemolytic activity and increment of accumulation in the target organs of the disease (leishmaniasis). Oryzalin (ORZ) is a dinitroaniline that has attracted increasing interest for the treatment of leishmaniasis. The possible use of ORZ as an antiparasitic agent is limited by low water solubility associated with an in vivo rapid clearance. The aim of this work was to overcome these unfavorable pharmaceutical limitations potentiating ORZ antileishmanial activity allowing a future clinical use. This was attained by incorporating ORZ in appropriate liposomes that act simultaneously as drug solvent and carrier delivering ORZ to the sites of Leishmania infection. The developed ORZ liposomal formulations efficiently incorporated and stabilised ORZ increasing its concentration in aqueous suspensions at least 150 times without the need of toxic solvents. The incorporation of ORZ in liposomes reduced the in vitro haemolytic activity and cytotoxicity observed for the free drug, while ORZ exhibits a stable association with liposomes during the first 24h after parenteral administration, significantly reducing ORZ blood clearance and elimination from the body. Simultaneously, an increased ORZ delivery was observed in the main organs of leishmanial infection with a 9–13-fold higher accumulation as compared to the free ORZ. These results support the idea that ORZ performance was strongly improved by the incorporation in liposomes. Moreover, ORZ liposomal formulations can be administrated in vivo in aqueous suspensions without the need of toxic solvents. It is expected an improvement in the therapeutic activity of liposomal ORZ that will be tested in future work.
ISSN:0939-6411
1873-3441
DOI:10.1016/j.ejpb.2012.06.013